142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

298868
Postpartum Care and the Provision of Effective Postpartum Contraceptive Methods in California's Medicaid Program

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Wednesday, November 19, 2014 : 8:30 AM - 8:50 AM

Monica Barr, MPH , Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, Sacramento, CA
Mary Bradsberry , Bixby Center for Global Reproductive Health (Department of Obstetrics, Gynecology and Reproductive Sciences), University of California, San Francisco, Sacramento, CA
Michael Howell, MA , Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Sacramento, CA
Michael Policar, MD, MPH , Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Sacramento, CA
Philip Darney, MD, MSc , Bixby Center for Global Reproductive Health, University of California, San Francisco, San Francisco, CA
Heike Thiel de Bocanegra, Ph.D., M.P.H. , Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Sacramento, CA
Postpartum care is an important opportunity for assessment of a woman’s health following delivery. One important component of postpartum care is discussion and potential provision of postpartum contraception, which can enable optimal birth spacing that supports healthy maternal and infant health outcomes. The HEDIS Postpartum Care Rate Measure defines postpartum care as pelvic exams or visits focused on postpartum health that occur 21 to 56 days after delivery. Although discussing contraception is an important component of postpartum care, most billing codes for family planning visits do not satisfy the HEDIS measure. We used administrative data from California’s Medicaid program, Medi-Cal, to identify deliveries, assess the type of postpartum visit received, and find evidence of contraceptive dispensing up to 90 days after delivery. Of 247,657 Medi-Cal deliveries between November 6, 2011 and November 5, 2012, 47.3% had a claim for a HEDIS-defined postpartum visit, an additional 7% had a family planning office visit, and 19.7% were seen for other medical reasons. Contraceptive claims were found for half of women with a postpartum visit and 73.3% of women with a family planning office visit. Only 20.8% of women who were seen for other medical reasons received contraception. We will describe the demographics of women who received contraceptives following a postpartum office visit, and further examine the scope of services received. The findings suggest that there are opportunities to both increase postpartum contraceptive use and encourage clinicians to take advantage of opportunities to inquire about or refer women for postpartum care.

Learning Areas:

Provision of health care to the public

Learning Objectives:
Describe utilization of postpartum care and postpartum contraception by California Medicaid clients. Compare rates of postpartum contraceptive provision based on both provider type and the services received during the postpartum period. Discuss the implications of these contraceptive dispensing patterns on postpartum care provision.

Keyword(s): Contraception, Perinatal Health

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have a Masters of Public Health with an emphasis in Maternal and Child Health, and 3 years of research experience in reproductive health and family planning. As a statistician on the evaluation team for California's Family PACT program, my interests include access to and utilization of effective contraceptive methods.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.